ASCO submitted testimony to the U.S. House and Senate Appropriations Committees urging them to increase funding for the National Institutes of Health, National Cancer Institute, and Food and Drug Administration.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
ASCO joined the Alliance for Childhood Cancer on Capitol Hill for the 8th Annual Childhood Cancer Action Day, where advocates met directly with Members of Congress and their staff about cancer policy priorities related to pediatric cancer.
During the Action Day, advocates urged Members of Congress to:
Today, ASCO is kicking off its Fiscal Year (FY) 2020 advocacy campaign in support of increased funding for federal cancer research. The launch of this year’s advocacy effort comes as Congress is beginning its work to craft FY 2020 appropriations bills. As part of the campaign, ASCO is urging Congress to provide $41.6 billion to the National Institutes of Health (NIH) – a $2.5 billion increase from FY 2019 – and $6.5 billion to the National Cancer Institute (NCI).
ASCO joined hundreds of other patient groups, scientific societies, and research and health care institutions in urging members of Congress to increase federal funding for cancer research and prevention in the Fiscal Year (FY) 2020 funding bill.
"We strongly oppose the White House budget proposal for Fiscal Year (FY) 2020, which would stall our nation’s progress against cancer and impede access to needed care for the millions of Americans dealing with cancer. The proposal would make drastic, unprecedented cuts to the U.S. Department of Health and Human Services—which houses the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Centers for Medicare & Medicaid Services (CMS)."
On February 12, 2019, ASCO leadership and members of the society’s Government Relations Committee met with representatives from key federal agencies, advisory groups, and other stakeholder organizations to discuss top cancer policy priorities. The meetings focused on access to clinical trials, drug pricing, step therapy, drug shortages, Medicaid waivers and other issues affecting people with cancer.
A new global resource that includes data on thousands of inherited variants in the BRCA1 and BRCA2 genes will help inform the understanding of cancer risk. Wendy Rubinstein, MD, PhD, FACP, FACMG, and Deputy Medical Director of CancerLinQ, LLC, a wholly owned nonprofit subsidiary of ASCO, served as a co-author of the new paper published this week in PLOS Genetics detailing the development of the new resource, BRCA Exchange.